Tissue factor pathway inhibitor 2 (TFPI2) mRNA (TFPI2 mRNA)

Tissue factor pathway inhibitor 2 (TFPI2), also known as placental protein 5, is a 32-kDa Kunitz-type serine protease inhibitor primarily localized in the extracellular matrix (UniProt P48307). It functions as a critical regulator of matrix remodeling by inhibiting a variety of serine proteases, including plasmin, trypsin, and the tissue factor-activated factor VII complex (PubMed: 22134929). In the context of oncology, TFPI2 is recognized as a potent tumor suppressor; however, its expression is frequently lost in various malignancies—such as glioblastoma, pancreatic, and colorectal cancers—due to transcriptional silencing via promoter hypermethylation (PubMed: 15642714). This loss of TFPI2 facilitates increased protease activity, promoting tumor cell invasion, metastasis, and angiogenesis. Consequently, TFPI2 mRNA has emerged as a therapeutic target for restoration strategies, including the use of demethylating agents like Decitabine to reactivate the endogenous gene or the delivery of synthetic mRNA to replenish protein levels. Beyond its role in cancer, TFPI2 is also implicated in cardiovascular diseases and pregnancy-related complications like preeclampsia.

Other names

Placental protein 5PP5TFPI-2Kunitz-type serine protease inhibitor TFPI-2REF-1

Restoration of tumor suppressor function through epigenetic reactivation or mRNA replacement to inhibit extracellular matrix-degrading proteases.